MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

LY-2584702 hydrochloride

CAS No. : 1082948-81-9

MCE 国际站：LY-2584702 hydrochloride

产品活性：LY-2584702 hydrochloride 是一种 ATP 竞争性的选择性 p70S6K 抑制剂，IC₅₀ 为 4 nM。LY-2584702 抑制 S6K1 的 IC₅₀ 为 2 nM。

研究领域：MAPK/ERK Pathway

作用靶点：Ribosomal S6 Kinase (RSK)

In Vitro: LY-2584702 (LY2584702) inhibits phosphorylation of the S6 ribosomal protein (pS6) in HCT116 colon cancer cells with an IC₅₀ of 0.1-0.24 μM. In S6K1 enzyme assay, the IC₅₀ of LY-2584702 (LY2584702) is 2 nM. For pS6 inhibition in cells, the IC₅₀=100 nM. LY-2584702 has some activity against the S6K-related kinases MSK2 ａnd RSK at high concentrations (enzyme assay IC₅₀=58-176 nM). LY-2584702 inhibits S6K activity in EOMA cells, as determined by the phosphorylation of its downstream effector S6, in a dose-dependent manner. Proliferation of A549 is significantly inhibited by LY-2584702 (LY2584702) treating over 24 h at 0.1 μM (P<0.05); ａnd the trend of decline is more conspicuous with longer treatment and/or with the increased drug concentration (all P<0.05). Similar results are also observed in SK-MES-1, although the obvious inhibition is led by LY-2584702 at 0.6 μM (P<0.05), much higher than that of A549.

In Vivo: LY-2584702 demonstrates significant single-agent efficacy in both U87MG glioblastoma ａnd HCT116 colon carcinoma xenograft models at two dose levels of 2.5 mg/kg twice daily (BID) ａnd 12.5 mg/kg BID. LY-2584702 demonstrates statistically significant tumour growth reduction at TMED50 (threshold minimum effective dose 50%) (2.3 mg/kg) ａnd TMED90 (10 mg/kg) in the HCT116 colon carcinoma xenograft model. To examine the role of S6K in vivo, EOMA cells expressing shAkt3 are implanted in nu/nu mice, then treated for 14 days with LY-2584702 or Rapamycin. Analysis of tumors removed after 14 days shows that LY-2584702 inhibits S6 phosphorylation almost as effectively as Rapamycin. Loss of Akt3 increases tumor growth as compared with pLKO. LY-2584702 treatment alone does not significantly affect the growth of pLKO tumors. However, LY-2584702 significantly reduces the growth of tumors with shAkt3.

相关产品：PF-4708671 | Carnosol | Pluripotin | LJH685 | Sodium Salicylate | LJI308 | Quercitrin | SL 0101-1 | CKI⁻⁷ free base | AT7867 dihydrochloride | BRD7389 | Eudesmin | SM1⁻⁷1

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。